GlassScriptPhysician profile
Teresa West
NPI 1821299652
$7,068.35
in general payments reported to CMS, 2019-2025
19 companies · $2,077 in 2025
The $2,077 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $387 · 2022: $121 · 2023: $3,328 · 2024: $1,156 · 2025: $2,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,563 · Consulting Fee: $2,452 · Travel and Lodging: $533 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,562.89 |
| Consulting Fee | $2,452.20 |
| Travel and Lodging | $533.09 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $3,353.00 | 2023-2025 | Rejoyn |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $730.37 | 2024-2025 | Caplyta |
| Abbvie INC. | $477.52 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $378.26 | 2021-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $373.42 | 2021-2024 | |
| Vanda Pharmaceuticals INC. | $366.98 | 2024-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $326.47 | 2024-2025 | Spravato |
| Alkermes, INC. | $265.84 | 2024-2025 | Lybalvi, Aristada, Vivitrol |
| Supernus Pharmaceuticals, INC. | $158.52 | 2021-2025 | Qelbree |
| Axsome Therapeutics, INC. | $122.51 | 2024-2025 | Auvelity |
| Corium, LLC | $110.73 | 2024-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $103.42 | 2024-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $72.60 | 2025 | Jornay Pm |
| Lundbeck LLC | $68.72 | 2025 | Rexulti |
| Tris Pharma INC | $50.43 | 2021-2025 | Dyanavel Xr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $32.11 | 2025 | Veozah |
| Sage Therapeutics, LLC | $29.67 | 2025 | Zurzuvae |
| Teva Pharmaceuticals USA, INC. | $28.97 | 2025 | Austedo Xr |
| Neos Therapeutics, LP | $18.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teresa West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.